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Abstract
Background: Carotid endarterectomy (CEA) has been the standard in atherosclerotic stroke prevention for over 2
decades. More recently, carotid artery stenting (CAS) has emerged as a less invasive alternative for revascularization.
The purpose of this study was to investigate whether an increase in stenting parallels a decrease in
endarterectomy, if there are specific patient factors that influence one intervention over the other, and how these
factors may have changed over time.
Methods: Using a nationally representative sample of US hospital discharge records, data on CEA and CAS
procedures performed from 1998 to 2008 were obtained. In total, 253,651 cases of CEA and CAS were investigated
for trends in utilization over time. The specific data elements of age, gender, payer source, and race were analyzed
for change over the study period, and their association with type of intervention was examined by multiple logistic
regression analysis.
Results: Rates of intervention decreased from 1998 to 2008 (P < 0.0001). Throughout the study period,
endarterectomy was the much more widely employed procedure. Its use displayed a significant downward trend
(P < 0.0001), with the lowest rates of intervention occurring in 2007. In contrast, carotid artery stenting displayed a
significant increase in use over the study period (P < 0.0001), with the highest intervention rates occurring in 2006.
Among the specific patient factors analyzed that may have altered utilization of CEA and CAS over time, the
proportion of white patients who received intervention decreased significantly (P < 0.0001). In multivariate
modeling, increased age, male gender, white race, and earlier in the study period were significant positive
predictors of CEA use.
Conclusions: Rates of carotid revascularization have decreased over time, although this has been the result of a
reduction in CEA despite an overall increase in CAS. Among the specific patient factors analyzed, age, gender, race,
and time were significantly associated with the utilization of these two interventions.
Background
Stroke is the fourth leading cause of mortality in the Uni-
ted States, accounting for over 130,000 deaths each year
[1]. More than 85% of all strokes are ischemic in origin
[2], with approximately 20% of those attributable to steno-
sis of the carotid artery [3]. Interventions aimed at primary
or secondary stroke prevention in patients with carotid
stenosis have evolved over time. Throughout the 1990s,
several randomized clinical trials among symptomatic
patients (defined as transient or permanent focal neurolo-
gical deficits) found that carotid endarterectomy (CEA)
was superior to, at the time, best medical management
[4,5]. This benefit was most significant in patients with
greater than 70% stenosis. Similar results were noted
among asymptomatic patients. In a sample of 444 men
from the VA medical system, Hobson et al. [6] noted a sig-
nificant reduction in adverse events in the surgery arm of
the trial as compared to the medical management arm.
Larger and more inclusive studies have reiterated these
findings [7,8]. However, CEA is an invasive surgical proce-
dure, and carries the associated risks of such.
Toward the later 1990s, carotid artery stenting (CAS)
emerged as a less invasive procedure for revascularization.
Despite this advantage, it was unclear whether CAS con-
ferred therapeutic benefit equal to that of CEA with
respect to stroke prevention. Several clinical trials have
attempted to address this question, with somewhat
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any medium, provided the original work is properly cited.conflicting results. In studies among symptomatic patients,
both the EVA-3 S and SPACE trials failed to show non-
inferiority of CAS over CEA in reducing the number of
endpoint events [9,10]. Other studies involving both symp-
tomatic and asymptomatic patients found that CAS was
either not inferior to [11] or not significantly better than
[12] CEA. However, in contrast to SPACE and the early
phase of EVA-3 S, CAS was performed with embolic pro-
tection in the majority of subjects in both of these studies.
With respect to procedural risk, in 2010, the Interna-
tional Carotid Stenting Study (ICSS) reported that the
risk of stroke, death, or myocardial infarction (MI) was
significantly higher in the group assigned to stenting [13].
It should be noted that follow-up was for 120 days and
embolic protection was not mandated in the study. A
later meta-analysis of EVA-3 S, SPACE, and ICSS data
f o u n dt h a te s t i m a t e dr i s kw i t hC A Sw a st w i c et h a to f
CEA in patients greater than age 70 [14]. Similarly, the
risk for stroke, MI, or death with CAS significantly
increased with age [15]. There was no age-associated
increase noted for CEA. There is also evidence from the
CREST trial that women may be at higher risk with CAS
as compared to CEA [16].
It now seems clear that the relative benefits of an inter-
vention must be assessed within the context of the indivi-
dual patient in which it is to be implemented. Patients
under the age of 70 or who were excluded from CEA due
to high surgical risk were found to have superior outcomes
with CAS over CEA or medical management [12]. How-
ever, CEA appears to provide the greater benefit to older
patients with symptomatic disease [13]. While evidence-
based referral of one intervention over the other is pre-
sently ambiguous, CAS should be offered as an alternative
to surgery for qualified candidates [17]. The number of
those qualified, however, is currently limited by a restric-
tion on CAS reimbursement by the Centers for Medicare
and Medicaid Services (CMS), an important primary payer
of the procedure. At present, stenting (with embolic pro-
tection) is reimbursed by the CMS only for those patients
excluded from CEA due to high surgical risk and who
have ≥ 70% symptomatic stenosis, or who have sympto-
matic stenosis ≥ 50% or asymptomatic stenosis ≥ 80% and
who are enrolled in an FDA-approved clinical trial [18].
In an effort to describe CEA and CAS utilization over
time, this study examined the respective prevalence of
these interventions in the Nationwide Inpatient Sample
(NIS) annually from 1998 to 2008. The NIS is a nation-
ally-representative database of US hospital discharges, and
provides comprehensive information across a range of
data variables. It was the aim of this study to report on
current CEA and CAS utilization trends with respect to
several specific patient demographic factors that may
influence intervention, and how these factors may have
changed over time. The guiding hypothesis of the study
was that CAS use has increased over the study period, and
that this increase parallels a decline in the rates of CEA.
Methods
Database and case identification
The Nationwide Inpatient Sample (NIS), part of the
Healthcare Cost and Utilization Project (HCUP), Agency
for Healthcare Research and Quality [19], was analyzed
annually from 1998 through 2008 This database contains
no direct patient identifiers and so is consistent with the
definition of “limited data set” under the HIPAA Privacy
Rule. For 2008, the 20% stratified sample of the NIS
included over eight million discharge records among
1052 participating hospitals in 42 states. Population esti-
mates were generated by incorporating provided dis-
charge weights. From this database, records with a
procedure code for carotid endarterectomy were directly
i d e n t i f i e db yt h eb yI C D - 9 - C Mp r o c e d u r ec o d e3 8 . 1 2 ,
which was used throughout the study period. For years
2004 through 2008, carotid artery stenting cases were
identified by the ICD-9-CM procedure code 00.63. As
this procedure code was not included in ICD-9-CM cod-
ing or the NIS before October 1, 2004, a more indirect
approach was required to capture CAS cases prior to this
time. To do so, the algorithm of Goodney et al. [20] was
employed. Briefly, all records with a procedure code for
placement of a non-coronary artery stent (39.90 for years
1998 through 2001, 39.90 and 00.55 for years 2002
through 2008) were obtained. These records were then
limited to those in which there was also an ICD-9-CM
diagnosis code for cerebrovascular disease (362.30,
362.32, 362.33, 362.34, 362.36, 362.84, 362.89, 433.1,
433.10, 433.11, 433.3, 433.30, 433.31, 433.9, 433.90,
433.91, 435.9, 437.9, and 447.1). In order to exclude
those records in which a peripheral stent was placed in a
vessel other than the carotid artery, cases with a diagnos-
t i cc o d ef o rp e r i p h e r a lv a s c ular disease were removed
(440.2, 440.20, 440.21, 440. 22, 440.23, 440.24, 440.29,
443.8, 443.81, 443.82, 443.89, and 443.9). Also, any record
with missing information for age, gender, payer source,
and race were excluded. For age, only patients between
the ages of 18 and 99 were included, with patients age 90
to 99 grouped to age 90 for analysis. This study was
approved by the University of Rochester Medical Center
Research Subjects Review Board (RSRB 00036477)
Statistical analysis
After isolating CEA and CAS cases for each year of the
study period, data sets were concatenated in order to
permit analysis of trends over time. To determine if the
specific patient characteristics of age, gender, payer
source, and race changed significantly from 1998 to
2008, univariate models were constructed. In these mod-
els, year was treated as the independent variable and its
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dependent variable over time. Age was treated as a con-
tinuous variable and analyzed using linear regression,
while gender (male = 0), payer source (Medicare = 1),
and race (white = 1) were dichotomized and analyzed
using logistic regression. In the multiple logistic regres-
sion models, CEA or CAS (whether or not the discharge
record contained a procedure code for CEA or CAS)
was treated as the dependent variable, and age, gender,
time and categorical (non-dichotomized) payer source
and race as the independent variables. Statistical tests
were two-sided, with P-values less than 0.05 considered
significant. All analyses were performed with SAS 9.2
(SAS Institute, Cary, CA).
Results
Trends in CEA and CAS utilization
From 1998 to 2008, 253,651 discharge records with a
procedure code for either CEA or CAS were obtained.
There was an average of 300 CEA and CAS procedures
performed per 100,000 discharges per year. The number
of procedures performed per year decreased significantly
(P < 0.0001) over the study period, from a high of 358
in 1998 to a low of 262 in 2007 (Table 1).
Nearly 92% (230,586) of all procedures were for endar-
terectomies. There was a statistically significant reduction
(P < 0.0001) in the number of CEA procedures performed
over time, with the lowest rate occurring in 2007. The
remaining 8% (23,065) of records coded directly or indir-
ectly for carotid artery stenting. There was an overall
increase in the use of stenting over the study period, from
a low of 9 procedures per 100,000 discharges in 1998, to a
high of 56 per 100,000 discharges in 2006. This trend was
statistically significant (P < 0.0001). Table 2 lists the num-
ber of records with a procedure code for CEA, the number
of combined (indirectly- and directly-coded) CAS cases,
and the number of these records per 100,000 discharges
for each year of the study period.
T h en u m b e ro fC E A ,C A S ,a n dt o t a lC E Aa n dC A S
procedures performed from 1998 to 2008 is presented
graphically in Figure 1.
Trends in patient-specific factors
The reduction in CEA and increase in CAS rates noted
above may have been influenced by a change in specific
patient factors over time. To investigate these changes
in those who received either procedure, mean age, the
percentage of male patients, patients with Medicare
listed as the primary payer, and patients identifying as
white were examined for each year of the study period.
Univariate logistic regression models were used to test
for a change in each of these factors over time. Among
the models tested, only race changed significantly over
the study period (P < 0.0001). The percentage of
patients identifying as white who received either CEA or
CAS decreased from a high of 92.87% in 1998, to a low
of 87.28% in 2008. This information is presented in
Table 3.
Influences on CEA and CAS utilization over Time
To examine the possible confounding effect of changes
in the patient demographic factors noted above on CEA
and CAS utilization, multiple logistic regression was
performed. In the multivariate models, primary payer
source and race were treated as categorical variables.
Age, gender, race and time were found to significantly
predict carotid endarterectomy use. Among these ele-
ments, female gender, non-white race, and time pre-
dicted lower CEA use. The results of this model are
presented in Table 4. For CAS, age, gender, race, and
year were again found to contribute significantly to the
prediction of intervention, however, their influence was
Table 1 Total number of discharges, number of CEA and CAS records, and procedures per 100,000 discharges
Year Discharges Combined CEA and CAS records CEA and CAS Procedures per 100,000 Discharges
1998 6,827,350 24,421 358
1999 7,198,929 24,252 337
2000 7,450,992 24,646 331
2001 7,452,727 24,716 332
2002 7,853,982 23,047 293
2003 7,977,728 23,011 288
2004 8,004,572 21,413 268
2005 7,995,048 21,224 265
2006 8,074,825 22,555 279
2007 8,043,415 21,040 262
2008 8,158,381 23,326 286
N = 85,037,949 N = 253,651 Mean = 300
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race, and time all positively predicted stenting.
Discussion and conclusion
In this report it was found that rates of overall carotid
revascularization have decreased from 1998 to 2008 in a
nationally-representative sample of US hospital discharge
records. This reduction was noted even as the median
age of US adults increased over the study period [21].
The decrease in revascularization was primarily the result
of a reduction in the number of carotid endarterectomy
procedures, despite a realized increase in carotid artery
stenting. Between 1998 and 2008, the rate of CEA
decreased by 36%, while that of CAS increased by 5%.
These results are in agreement with, and an extension of,
previous reports investigating utilization trends of these
interventions [20,22,23].
At present, there is lack of clear clinical directive on
which intervention may be superior for primary or sec-
ondary stroke prevention. As reported here, carotid
endarterectomy has been, and likely will continue to be,
the much more widely utilized procedure. From 1998 to
2008, CEA use has decreased by about one third, yet the
overall rate of procedures during that time exceeds that
of CAS by an order of magnitude. If patients most at risk
for procedural complications avoid the surgery, the
5-year risk of stroke or death may be reduced 5 to 6% as
compared to medical management alone [7]. However,
two caveats must be addressed. First, absolute risk reduc-
tion is much more nuanced than the quoted 5 to 6%
when patient-specific factors and longer follow-up times
are taken into account [24]. Second, medical manage-
ment of stroke has been refined since early CEA trials
comparing the two approaches, and today nearly all
patients at risk for stroke are prescribed antihypertensive,
antiplatelet, and lipid-lowering therapies. Such an aggres-
sive regimen may be effectively reducing stroke risk and
the subsequent need for surgery, particularly in asympto-
matic patients [25].
In contrast, rates of carotid artery stenting were found
to increase significantly over the study period. The high-
est rates of intervention were noted in 2006, with a 25%
decrease from 2006 to 2008. Interestingly, nearly the low-
est rates of CEA occurred in 2006. In 2004, the results of
the SAPPHIRE trial were published, indicating that CAS
with embolic protection was not inferior to CEA for the
prevention of stroke in select patients [11]. That same
year the first FDA-approved carotid artery stent was
introduced, and, in early 2005, the CMS expanded its
reimbursement policies for CAS [18]. Investigation of a
correlation between these events is beyond the scope of
this work, but it is an intriguing prospect. It remains to
Table 2 Number of CEA records, combined CAS records, and number of procedures per 100,000 discharges
Year Discharges CEA
Records
CEA Procedures per 100,000
Discharges
Combined CAS
Records
CAS Procedures per 100,000
Discharges
1998 6,827,350 23,782 348 639 9
1999 7,198,929 23,214 322 1,038 14
2000 7,450,992 23,612 317 1,034 14
2001 7,452,727 23,294 313 1,422 19
2002 7,853,982 21,604 275 1,443 18
2003 7,977,728 21,346 268 1,665 21
2004 8,004,572 19,442 243 1,971 25
2005 7,995,048 18,419 230 2,805 35
2006 8,074,825 18,069 224 4,486 56
2007 8,043,415 17,944 223 3,096 38
2008 8,158,381 19,860 243 3,466 42
Total N =
85,037,949
N=
230,586
Mean = 273 N = 23065 Mean = 27
Figure 1 Trends in CEA and CAS utilization from 1998-2008.
Skerritt et al. BMC Neurology 2012, 12:17
http://www.biomedcentral.com/1471-2377/12/17
Page 4 of 7be seen if the overall increase in CAS reported here will
continue going forward. The recently-published CREST
[12] and ICSS [13] trials failed to provide consensus on
which procedure conferred the greater benefit, and so
future studies in this area will be welcomed. Of interest is
the SPACE2 trial, which will compare the effectiveness of
best medical management vs. CEA vs. CAS [26].
A primary aim of this study was to identify specific
patient demographic factors that may have changed over
time, and to examine their potential influence on proce-
dure rates. Among those factors analyzed, there was a
significant decrease in the percentage of patients identify-
ing as white who received intervention. This decrease
remained significant for total CEA and CAS rates, as well
as for CEA (P < 0.0001) and CAS (P = 0.02) indepen-
dently. However, whites were still the overwhelming reci-
pients of carotid revascularization. Although there is an
overall higher number of whites in the general population
[21], part of the explanation may also be that white
patients are more commonly affected by atherosclerotic
carotid artery disease than non-whites [27]. Within the
context of endarterectomy specifically, several studies
have provided some understanding into why minority
patients may be less likely to have surgery. Black patients
were found to have higher rates of complicating comor-
bid conditions [28] and faced increased barriers to quality
care [29]. In addition, there are racial differences in the
decision to have surgery, with blacks significantly more
averse than whites to CEA [30]. Despite these findings, it
has been reported that when clinically indicated and
adjusting for ancillary factors, any difference in the deliv-
ery of CEA between white and non-white patients is atte-
nuated [31].
When the additional factors of age, gender, payer source,
a n dt i m ew e r ei n c l u d e di nm u l t i v a r i a t em o d e l s ,i tw a s
found that age, gender, race, and time were significant pre-
dictors of either CEA or CAS. Increased age, male gender,
white race, and earlier in the study period were significant
positive predictors of CEA use. Payer source did not reach
statistical significance in either model, nor did it change
significantly over time in the univariate model. As noted
in Table 3, Medicare was listed as the primary payer in
73% of cases throughout the study period. Despite the cur-
rent reimbursement limitation for carotid artery stenting
by the CMS, rates continued to increase over the study
period. This may suggest that, other factors notwithstand-
ing, CAS delivery may accelerate should this limitation be
lifted in the future.
Several limitations to this study should be noted. First,
as described elsewhere, the algorithm used to capture car-
otid artery stenting prior to 2004 suffers from a lack of
certainty in the identification of “true” CAS cases [20].
However, any bias introduced as a result would be sys-
tematic, and tend not to influence the change in rates of
CAS over time. Also, the data used in this report was
taken from a de-identified, discharge-based database.
Therefore, the denominators used to calculate intervention
rates likely represent several non-unique patients, which
may artificially lower the numbers presented here. Finally,
this work is a comment on the change over time of CEA
and CAS, and as such, does not provide the ability to
explain unambiguously why these changes have occurred.
Importantly, the third side to the stroke prevention triad,
medical management, was excluded from analysis here.
How the revision in medical therapy for stroke and stroke
prevention has contributed to the change in rates in this
study population is unknown.
In conclusion, it was found that overall rates of carotid
revascularization have decreased from 1998-2008 in a
nationally-representative sample of US hospital discharges.
This decrease was primarily the result of a reduction in
the number of carotid endarterectomy procedures, despite
Table 3 Results of univariate logistic regression analysis testing for a change in each indicated variable over time
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 1998-2008
N 24,421 24,252 24,646 24,716 23,047 23,011 21,413 21,224 22,555 21,040 23,326 Slope/OR CI P-Value
Age, y
(SE)
70.97
(0.06)
70.95
(0.06)
71.11
(0.06)
71.25
(0.06)
71.25
(0.06)
71.04
(0.06)
70.9
(0.07)
71.03
(0.07)
71.12
(0.06)
71.16
(0.07)
71.06
(0.06)
0.005 -0.007-0.0016 0.41
% Male 57.26 57.64 57.29 57.3 56.92 56.8 57.05 57.42 57.39 57.32 57.72 1.001 0.998-1.003 0.63
% Medicare 71.72 71.73 73.1 73.19 74.68 74.95 73.07 73.7 73.92 73.43 70.98 1.002 1.000-1.005 0.08
% White 92.87 91.92 91.47 89.96 89.82 88.56 89.32 89.98 89.48 87.52 87.28 0.949 0.945-0.953 < 0.0001
Table 4 Results of multivariate logistic regression
analysis with CEA as the dependent variable and white
race as the reference demographic
Data Element OR CI P-Value
Age 1.018 1.016-1.020 < 0.0001
Gender 0.908 0.883-0.934 < 0.0001
Primary Payer Source 1.004 0.987-1.020 0.6617
Race: Black 0.633 0.594-0.674 < 0.0001
Race: Hispanic 0.772 0.723-0.825 < 0.0001
Race: Asian/Pacific Islander 0.623 0.550-0.706 < 0.0001
Race: Native American 0.617 0.513-0.724 < 0.0001
Race: Other 0.788 0.716-0.867 < 0.0001
Year 0.826 0.822-0.830 < 0.0001
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the patient-specific factors analyzed, race changed signifi-
cantly over time, and age, gender, race, and time signifi-
cantly predict utilization of intervention. Several recent
reports investigating the utility of CEA as compared to
C A Sf o rt h ep r e v e n t i o no fs t r o k eh a v eb e e np u b l i s h e d .
However, future work remains to adequately inform the
deployment of these interventions to the patients for
whom the greatest benefit will be conferred.
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